NRF2 (Nuclear factor erythroid 2-related factor 2) activator therapies represent a promising approach to treating neurodegenerative diseases by enhancing the cellular antioxidant response. The NRF2-KEAP1 pathway is a master regulator of antioxidant and cytoprotective gene expression, making it an attractive therapeutic target for conditions characterized by oxidative stress, including Alzheimer's disease, Parkinson's disease, ALS, FTD, and normal aging.
Pathway / Mechanism Diagram
graph TD
A["Normal Conditions"] --> B["Keap1 Binds NRF2"]
B --> C["NRF2 Ubiquitination"]
C --> D["Proteasomal Degradation"]
E["Oxidative Stress"] --> F["Keap1 Cysteine Modification"]
F --> G["NRF2 Release"]
G --> H["Nuclear Translocation"]
H --> I["ARE Binding"]
I --> J["HO-1: Heme Detoxification"]
I --> K["NQO1: Quinone Detoxification"]
I --> L["GST: Glutathione Conjugation"]
I --> M["Catalase, SOD"]
J --> N["Neuroprotection"]
K --> N
L --> N
M --> N
O["NRF2 Decline in Aging"] --> P["Reduced Antioxidant Defense"]
P --> Q["Oxidative Neurodegeneration"]
style N fill:#1b5e20,color:#e0e0e0
style Q fill:#ef5350,color:#e0e0e0
style H fill:#006494,color:#e0e0e0
Mechanism of Action
NRF2-KEAP1 Pathway
The NRF2-KEAP1 pathway is the central mechanism by which cells respond to oxidative stress:
NRF2 (Nuclear factor erythroid 2-related factor 2) activator therapies represent a promising approach to treating neurodegenerative diseases by enhancing the cellular antioxidant response. The NRF2-KEAP1 pathway is a master regulator of antioxidant and cytoprotective gene expression, making it an attractive therapeutic target for conditions characterized by oxidative stress, including Alzheimer's disease, Parkinson's disease, ALS, FTD, and normal aging.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Mechanism of Action
NRF2-KEAP1 Pathway
The NRF2-KEAP1 pathway is the central mechanism by which cells respond to oxidative stress:
NRF2 Transcription Factor: NRF2 is a basic leucine zipper transcription factor that regulates the expression of antioxidant and cytoprotective genes under conditions of oxidative stress[@nguyen2020].
KEAP1 Repressor: Under normal conditions, NRF2 is bound by KEAP1 (Kelch-like ECH-associated protein 1), which targets NRF2 for ubiquitination and proteasomal degradation[@kensler2007].
Oxidative Stress Response: When cells experience oxidative stress, cysteine residues on KEAP1 become oxidized, leading to release and stabilization of NRF2[@zhang2005].
ARE Activation: Stabilized NRF2 translocates to the nucleus and binds to Antioxidant Response Elements (ARE) in the promoter regions of target genes[@rushmore1991].
[Nguyen T et al., Nrf2: from prevention to oxidative stress in neurodegeneration (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32844062/)
[Kensler TW et al., Cancer chemoprevention through the Keap1-Nrf2 signaling pathway (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17208639/)
[Zhang DD et al., Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/16153700/)
[Rushmore TH et al., The antioxidant responsive element (1991) (1991)](https://pubmed.ncbi.nlm.nih.gov/1912210/)
[Calkins MJ et al., The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19395657/)
[Johnson DA et al., The Nrf2-ARE pathway: implication for neurological disease pathogenesis (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20872078/)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate